Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
Rheumatol Adv Pract 2024;8(1):rkae018 doi: 10.1093/rap/rkae018
This retrospective analysis by Weddell, et al. found no difference in IL-17Ai (secukinumab and ixekizumab) survival rates and no relationship between PsA or axSpA diagnosis and drug survival. They also noted lower survival figures at 2 years of treatment.
Patients included in the study had axSpA or PsA and were treated with secukinumab or ixekizumab up to December 2022 at the Leeds Teaching Hospitals Trust Specialist Spondyloarthritis Service. Cox regression analysis was performed to investigate the relationship between diagnosis
and length of drug survival.
Keywords:
